EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

A Case of Enfortumab Vedotin-Associated Diabetic Ketoacidosis With Severe Insulin Resistance in a Nondiabetic Woman

Rachel Hovelroud iD, Sarah Goh Xiu Ming iD, Donald S A McLeod iD, Peter J Donovan iD, Gary Ng iD, Maree Mungomery

JCEM Case Reports · 07.11.2024 · 2 (12)

DOI: 10.1210/jcemcr/luae212 ↗

Kurz gefasst

Fallbericht in der Zeitschrift JCEM Case Reports, online erschienen am 25.11.2024. Verfasst von Rachel Hovelroud und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes and Endocrinology, Townsville University Hospital, Douglas QLD 4814, Australia. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Enfortumab vedotin is a novel antibody-drug conjugate (ADC) approved to treat urothelial carcinoma. One rarely reported adverse effect has been life-threatening diabetic ketoacidosis (DKA) driven by profound insulin resistance. We report a case of a 62-year-old nondiabetic woman with metastatic urothelial carcinoma who experienced DKA following her third dose of enfortumab vedotin, with extreme insulin requirements of > 1000 units daily, and full resolution of insulin requirement by day 7 of admission. Including this case, 3 of 9 reported patients with enfortumab vedotin–associated DKA have survived. Monomethyl auristatin E (MMAE), the cytotoxic component of enfortumab vedotin, is the likely cause, although the exact mechanism remains unclear. This rare clinical event challenges the usual protocols and practice surrounding insulin infusion administration, and this case provides evidence to assist in understanding the mechanism by which enfortumab vedotin causes ketoacidosis.

Schlagwörter

Stichwörter der Autor:innen

antibody-drug conjugatediabetic ketoacidosisenfortumab vedotininsulin resistancemonomethyl auristatin Eurothelial carcinoma

Autor:innen und Institutionen

  • Department of Diabetes and Endocrinology, Townsville University Hospital, Douglas QLD 4814, Australia.
  • Department of Diabetes and Endocrinology, Royal Brisbane & Women's Hospital, Herston QLD 4006, Australia.
  • Department of Medical Oncology, Royal Brisbane & Women's Hospital, Herston QLD 4006, Australia.

ORCID-Profile: Rachel Hovelroud, Sarah Goh Xiu Ming, Donald S A McLeod, Peter J Donovan, Gary Ng

Zitieren

APA

Hovelroud, R., Goh Xiu Ming, S., McLeod, D. S. A., Donovan, P. J., Ng, G., & Mungomery, M. (2024). A Case of Enfortumab Vedotin-Associated Diabetic Ketoacidosis With Severe Insulin Resistance in a Nondiabetic Woman. JCEM Case Reports, 2(12). https://doi.org/10.1210/jcemcr/luae212

Vancouver

Hovelroud R, Goh Xiu Ming S, McLeod DSA, Donovan PJ, Ng G, Mungomery M. A Case of Enfortumab Vedotin-Associated Diabetic Ketoacidosis With Severe Insulin Resistance in a Nondiabetic Woman. JCEM Case Reports. 2024;2(12). doi:10.1210/jcemcr/luae212

BibTeX
@article{Hovelroud2024,
  author = {Hovelroud, Rachel and Goh Xiu Ming, Sarah and McLeod, Donald S A and Donovan, Peter J and Ng, Gary and Mungomery, Maree},
  title = {A Case of Enfortumab Vedotin-Associated Diabetic Ketoacidosis With Severe Insulin Resistance in a Nondiabetic Woman},
  journal = {JCEM Case Reports},
  year = {2024},
  volume = {2},
  number = {12},
  doi = {10.1210/jcemcr/luae212}
}
Kostenlos starten →